Thermo Scientific Imject Alum Adjuvant is a formulation of aluminum hydroxide and magnesium hydroxide that effectively stimulates the immune response for antibody production procedures when mixed and injected with prepared immunogens.
Alum is considerably easier to mix with immunogens than Freund's adjuvants, as it does not require laborious emulsification. Although its effects are less pronounced compared to Freund's complete adjuvant (CFA), Imject Alum produces sufficient stimulation when used with complex immunogens (i.e., those that have been prepared as conjugates with KLH or other immunogenic carrier proteins).
- Suspension of aluminum hydroxide and magnesium hydroxide
- Mild but effective adjuvant for substantial immunogens
- Ready to use: mix antigen directly with Imject Alum and inject
- The adjuvant of choice for allergy and immunogenicity testing with or without sensitization and challenge with fraction V ovalbumin (OVA) (see Moisan and Pongratz references)
- Disadvantage: does not elicit as strong an immune response as CFA; requires a strong immunogen
Adjuvants are nonspecific stimulators of the immune response. When mixed with an antigen or immunogen, adjuvants help to deposit or sequester the injected material thereby helping to increase antibody response. Adjuvants enhance the immune response to compounds that are already immunogenic; they do not confer immunogenicity to non-immunogenic haptens. To make prospective antigens more immunogenic, it is necessary to conjugate them to a carrier protein or some other complex, immunogenic molecule.
- Harlow, E. and Lane, D. (1988). Antibodies: A Laboratory Manual.Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, pp. 56-100.
- Moisan, J., et al. (2006). TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway. Am J Physiol Lung Cell Mol Physiol. 290:L987-L995.
- Pongratz, G., et al. (2006). The level of IgE produced by a B cell is regulated by Norepinephrine in a p38 MAPK- and CD23-dependent manner. J. Immunol. 177:2926-2938.
- Delamarre, L., et al. (2006). Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J. Exp. Med. 203:2049-2055.
- Ogunniyi. A.D., et al. (2007). Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect. Immun. 75:350-357.
Review of antibody production (immunogen preparation)
Imject Freund's Adjuvants (elicits a stronger immune response than Alum)
KLH, BSA and other Carrier Proteins